Archives

  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07

    • Kaempferol Attenuates Melanocyte Ferroptosis in Vitiligo via

    2026-06-02

    Kaempferol Attenuates Melanocyte Ferroptosis in Vitiligo via NF-κB/PTGS2 Axis

    Study Background and Research Question

    Vitiligo, a prevalent acquired depigmenting disorder, is characterized by the progressive destruction of functional epidermal melanocytes, affecting 0.5–2% of the global population. Despite advances in phototherapy and immunomodulation, therapeutic responses remain inconsistent, and recurrence is frequent. A central clinical challenge is the incomplete understanding of the precise cell death mechanisms responsible for melanocyte loss, particularly under the chronic oxidative and inflammatory microenvironment of vitiligo lesions. Recent evidence has highlighted ferroptosis—an iron-dependent, non-apoptotic form of regulated cell death—as a likely contributor to melanocyte injury, yet the upstream signaling events bridging oxidative stress and ferroptosis susceptibility are poorly defined. The reference study sought to unravel how kaempferol, a bioactive flavonoid with established antioxidant properties, modulates ferroptosis in human melanocytes and to clarify the role of the NF-κB/PTGS2 signaling axis in this context (Xu et al., 2026).

    Key Innovation from the Reference Study

    The core innovation of this work lies in the identification and mechanistic dissection of the NF-κB/PTGS2 axis as a critical link between inflammatory signaling and ferroptosis-mediated melanocyte damage in vitiligo. The study demonstrated that kaempferol robustly attenuates RSL3-induced ferroptosis in primary human melanocytes by inhibiting NF-κB nuclear translocation and downstream PTGS2 (COX-2) expression. By integrating transcriptomic, pharmacological, and clinical data, the research delineates a stress-responsive pathway that can be targeted to protect melanocytes from oxidative death—a significant step forward for both basic ferroptosis research and translational vitiligo therapy.

    Methods and Experimental Design Insights

    The investigators established an in vitro ferroptosis model using primary human melanocytes treated with RSL3, a potent inhibitor of GPX4 and a canonical ferroptosis inducer. This approach recapitulated key features of ferroptotic cell death, including lethal lipid peroxidation, glutathione depletion, and characteristic mitochondrial shrinkage. Multi-dimensional data collection included:
    • High-throughput transcriptomic profiling (RNA-seq) to identify differentially expressed genes and signaling nodes during ferroptosis and kaempferol treatment.
    • Network pharmacology and molecular docking to connect kaempferol's putative targets with ferroptosis-related genes.
    • Immunofluorescence and RT-qPCR to validate NF-κB (p65) nuclear translocation and PTGS2 expression.
    • Pharmacological inhibition using BAY 11-7082 to probe the functional relevance of NF-κB signaling.
    • Clinical validation with lesional skin biopsies from vitiligo patients, assessing both ferroptosis markers and NF-κB/PTGS2 pathway activation (Xu et al., 2026).

    Protocol Parameters

    • Ferroptosis induction in melanocytes: Treat primary human melanocytes with RSL3 (1–5 μM) for 24 hours to trigger ferroptotic cell death.
    • Kaempferol protection assay: Pre-treat cells with kaempferol (concentration range: 10–30 μM, 2 hours prior to RSL3) to assess anti-ferroptosis efficacy.
    • Oxidative stress assay: Measure intracellular ROS, lipid peroxidation (4-HNE), and glutathione levels post-treatment.
    • NF-κB/PTGS2 pathway assessment: Quantify p65 nuclear translocation (immunofluorescence), PTGS2 mRNA/protein (RT-qPCR, IHC), and downstream targets.
    • Clinical sample analysis: Stain vitiligo patient skin sections for ferroptosis and NF-κB/PTGS2 markers.

    Core Findings and Why They Matter

    The study’s findings demonstrate that RSL3-induced ferroptosis in melanocytes is characterized by excessive lipid peroxidation, mitochondrial morphological changes, and glutathione depletion—core hallmarks of iron-dependent, non-apoptotic cell death. Kaempferol pretreatment significantly blunted these effects, preserving melanocyte viability and redox homeostasis. Transcriptomic and network analyses converged on PTGS2 as a pivotal gene regulated by NF-κB and implicated in ferroptosis susceptibility. Kaempferol blocked NF-κB p65 nuclear translocation, suppressing PTGS2 transcription and thereby mitigating ferroptotic stress. Importantly, pharmacological inhibition of NF-κB phenocopied kaempferol’s protective effects, confirming the functional relevance of the pathway. Clinical biopsy analysis mirrored these mechanistic findings: lesional vitiligo skin exhibited upregulated NF-κB/PTGS2 signaling and ferroptosis markers, supporting the translational significance of targeting this axis. Collectively, these results provide strong evidence that the NF-κB/PTGS2 pathway links inflammatory and oxidative stress signals to ferroptosis-mediated melanocyte injury in vitiligo, and that kaempferol can interrupt this deleterious cascade (Xu et al., 2026).

    Comparison with Existing Internal Articles

    While the reference paper focuses on melanocyte ferroptosis in vitiligo, a substantial body of internal literature examines ferroptosis mechanisms in cancer biology and redox regulation. For instance, "Erastin and the Evolving Frontier of Ferroptosis" and "Erastin: Ferroptosis Inducer for Cancer Biology & Redox Research" detail how Erastin—a well-characterized ferroptosis inducer—selectively triggers iron-dependent cell death in RAS- or BRAF-mutant tumor models via cystine/glutamate antiporter system Xc⁻ inhibition. These articles provide mechanistic context and experimental protocols for manipulating ferroptosis in oncology and highlight parallels in redox pathway vulnerability. The vitiligo study extends these insights to non-malignant cells, underlining the universal relevance of ferroptosis across disease domains and emphasizing the role of inflammation-coupled signaling (NF-κB/PTGS2) in mediating susceptibility.

    Limitations and Transferability

    Despite its strengths, the study is limited by its primary reliance on in vitro melanocyte cultures and ex vivo patient samples. The precise in vivo relevance of kaempferol-mediated NF-κB/PTGS2 inhibition in the complex skin microenvironment warrants further exploration in animal models and future clinical studies. Additionally, while the findings robustly implicate the NF-κB/PTGS2 axis in melanocyte ferroptosis, other inflammatory or metabolic pathways may contribute to disease pathogenesis and should be systematically investigated. The transferability of these results to other cell types or forms of regulated cell death remains to be established, although the methodological framework—combining transcriptomics, pharmacology, and clinical validation—offers a template for broader ferroptosis research.

    Research Support Resources

    For researchers seeking to model ferroptosis or dissect redox vulnerabilities in diverse cell systems, optimized reagents and protocols are essential. The small molecule Erastin (SKU B1524) from APExBIO is widely used as a reference ferroptosis inducer in oxidative stress assays, especially within cancer biology research targeting the RAS-RAF-MEK signaling pathway. Erastin enables precise induction of iron-dependent, non-apoptotic cell death and can be integrated into workflows analogous to those described in the vitiligo study, supporting further investigation of oxidative stress and inflammatory signaling in ferroptosis. For detailed mechanistic background and practical guidance, internal articles such as "Erastin and the Evolving Frontier of Ferroptosis" offer actionable protocols and troubleshooting advice tailored to ferroptosis research workflows.